Composition of OX40 bivalent nucleic acid aptamer and CpG, preparation method and application

By developing the composition of OX40 divalent nucleic acid aptamer and CpG, the existing OX40 antibody agonist drugs have been solved, and efficient tumor immunotherapy has been achieved, with the inhibition of tumor recurrence and reduction of treatment. cost effect.

CN118949026APending Publication Date: 2024-11-15SOUTHWEST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411277296.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing OX40 antibody agonist drugs are costly and have strong immunogenicity, which limits their wide application in tumor treatment.

Method used

The composition of OX40 divalent nucleic acid aptamer and CpG was developed, and biROX40 was obtained by self-assembly of RNA-OX40a and DNA scaffolding, combining CpG agonists to form an immunoagonist with high stability and low cost for tumor immunotherapy.

Benefits of technology

This composition can specifically recognize and bind OX40 receptors on the surface of tumor cells, promote T cell activation and memory T cell production, inhibit Tregs proliferation, achieve specific immune activation and clearance of tumor cells, and have the ability to inhibit tumor recurrence and reduce treatment costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949026A_ABST
    Figure CN118949026A_ABST
Patent Text Reader

Abstract

The invention relates to a composition of an OX40 bivalent nucleic acid aptamer and CpG as well as a preparation method and application of the composition. The composition of the OX40 divalent nucleic acid aptamer and the CpG comprises a mixed solution of the OX40 divalent nucleic acid aptamer and a Toll-like receptor 9 (TLR9) agonist CpG. The preparation method of the composition comprises the following steps: mixing and annealing RNA-OX40a-T and RNA-OX40a-B to obtain a first mixed solution; then sequentially carrying out transcription, purification and vacuum spin-drying to obtain RNA-OX40a; mixing with a DNA bracket, annealing and assembling to obtain biROX40; and mixing the OX40 bivalent nucleic acid aptamer with a buffer solution containing CpG to obtain a mixed solution of the OX40 bivalent nucleic acid aptamer and the CpG agonist. The invention also provides application of the composition of the OX40 bivalent nucleic acid aptamer and the CpG in preparation of medicines for tumor immunotherapy. The problems that an existing OX40 antibody agonist medicine is high in cost, high in immunogenicity and the like are solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomaterials, and in particular to a composition, a preparation method and an application of an OX40 bivalent nucleic acid aptamer and CpG. Background Art

[0002] In the vast field of tumor immunotherapy, immune checkpoint therapy, as a cutting-edge and highly effective strategy, has made significant progress in recent years by precisely regulating the functions of immune cells through the combination of agonists and inhibitors to form immune checkpoint drugs. Among them, the regulation of OX40, a key immune checkpoint, is considered to be an important way to enhance anti-tumor immune responses. OX40 agonists can significantly enhance the body's anti-tumor ability by activating T cells and other immune cells, forming a powerful supplement to existing immunotherapy. However, current OX40 agonists mainly exist in the form of monoclonal antibodies, which have problems such as high cost, large batch differences, and potential immunogenicity, which limits their widespread application and the implementation of long-term treatment plans.

[0003] In order to overcome these limitations, researchers have begun to explore new alternative drugs. Among them, nucleic acid aptamers have attracted much attention due to their unique advantages. Nucleic acid aptamers, also known as "chemical antibodies", are obtained through SELEX technology screening and have the advantages of high affinity, low cost, small batch differences, and low immunogenicity. Studies have attempted to use OX40 aptamers in dendritic cell (DC) vaccines, but although preliminary results showed certain anti-tumor effects, significant therapeutic effects were only observed in a small number of experimental animals, suggesting that existing application forms have not yet fully utilized the full potential of OX40 aptamers. Therefore, it is urgent to explore new application forms to exert its anti-tumor effects. Summary of the invention

[0004] In view of this, the purpose of the present invention is to provide a composition, preparation method and application of OX40 bivalent nucleic acid aptamer and CpG to solve the problems of high cost and strong immunogenicity of existing OX40 antibody agonist drugs, and explore its new application in the treatment of lymphoma and other tumors.

[0005] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0006] The composition of OX40 bivalent nucleic acid aptamer and CpG comprises a mixed solution of OX40 bivalent nucleic acid aptamer and CpG agonist.

[0007] Preferably, the OX40 bivalent nucleic acid aptamer is biR OX40 ;

[0008] Preferably, the OX40 bivalent aptamer is obtained by self-assembly of RNA-OX40a and a DNA scaffold, and the nucleotide sequence of the RNA-OX40a (74 nt) is shown in SEQ ID NO:6.

[0009] Among them, SEQ ID NO:6 single-stranded nucleic acid:

[0010] GGGAGGACGAUGCGGCAGUCUGCAUCGUAGGAAUCGCCACCGUAUACUUUCCCACN R , N is any one of the four bases A, T, C, and G, R represents the number of bases, and the value of R is 19.

[0011] CpG is a potent agonist of Toll-like receptor 9 (TLR9) and is often used as an immune adjuvant due to its strong immunostimulatory ability.

[0012] In this application, tumor immunotherapy is performed by combining OX40 bivalent aptamer drugs with CpG, which has good therapeutic effects in animal experiments.

[0013] The present invention also provides a method for preparing a composition of OX40 bivalent nucleic acid aptamer and CpG, comprising the following steps:

[0014] S1, mixing RNA-OX40a-T and RNA-OX40a-B and annealing them to obtain a first mixed solution;

[0015] S2, transcribing the first mixed solution under the first temperature condition to obtain a second mixed solution;

[0016] S3, purifying the second mixed solution by gel electrophoresis to obtain a third mixed solution;

[0017] S4, purifying the third mixed solution by ethanol precipitation, and vacuum drying to obtain RNA-OX40a;

[0018] S5, RNA-OX40a was mixed with DNA scaffold for annealing and assembly to obtain biR OX40 ;

[0019] S6、BiR OX40 The aptamer was mixed with a buffer solution containing a CpG agonist to obtain a mixed solution of the OX40 bivalent nucleic acid aptamer and the CpG agonist.

[0020] The CpG agonist is CpG 1826. The sequence of CpG 1826 is shown in SEQ ID NO:5.

[0021] SEQ ID NO:5: T*C*C*A*T*G*A*C*G*T*T*C*C*T*G*A*C*G*T*T, * indicates the phosphorothioate backbone.

[0022] Preferably, in S1, RNA-OX40a-T and RNA-OX40a-B form a double-stranded template nucleic acid, which anneals to form a specific secondary structure.

[0023] Preferably, in S6, RNA-OX40a is a single-stranded nucleic acid, and the RNA-OX40a is mixed with a DNA scaffold and annealed to form a specific secondary structure.

[0024] Preferably, in said S1, the nucleotide sequence of RNA-OX40a-T is as shown in SEQ ID NO:7.

[0025] Preferably, in S2, the nucleotide sequence of RNA-OX40a-B is as shown in SEQ ID NO:8.

[0026] Among them, SEQ ID NO:7 single-stranded nucleic acid:

[0027] TTCTAATACGACTCACTATAGGGAGGACGATGCGGCAGTCTGCATCGTAGGAATCGCCACCGTATACTTTCCCACN R , N is any one of the four bases A, T, C, and G, R represents the number of bases, and the value of R is an integer between 15 and 19;

[0028] SEQ ID NO:8 Single-stranded nucleic acid:

[0029] N' R GTGGGAAAGTATACGGTGGCGATTCCTACGATGCAGACTGCCGCATCGTCCTCCCTATAGTGAGTCGTATTAGAA, N' and N are complementary bases, R represents the number of bases, and the value of R is an integer between 15 and 19.

[0030] Preferably, in S1, the molar ratio of RNA-OX40a-T to RNA-OX40a-B is 1.0-1.1:1.0, and the dosage is 1 μg.

[0031] Preferably, in S1, the annealing buffer used in the mixed annealing treatment is DEPC water.

[0032] Preferably, in S1, the procedure of the mixed annealing treatment is: incubation at 95°C for 5 min, incubation at 65°C for 30 min, incubation at 50°C for 30 min, incubation at 37°C for 30 min, incubation at 25°C for 30 min, and incubation at 4°C for more than 2 h.

[0033] Preferably, in S2, the first mixed solution is transcribed under the first temperature condition using a transcription kit.

[0034] Preferably, the transcription kit is selected from T7 RiboMAX TM Express kit, the buffer is RiboMAXTMExpress T7 2×Buffer. The amount of T7 RNA polymerase used is 2μL.

[0035] Preferably, in S2, the first temperature is 37°C.

[0036] Preferably, in S2, the time for transcribing the first mixed solution under the first temperature condition is 16 hours.

[0037] Preferably, in S5, the molar ratio of RNA-OX40a to DNA scaffold is 2.8-3.2:1.

[0038] Preferably, in S5, the DNA scaffold is DNA-OX40a-S.

[0039] The nucleotide sequence of DNA-OX40a-S (41 nt) is shown in SEQ ID NO:9.

[0040] Wherein, SEQ ID NO:9 single-stranded nucleic acid: N' R TTTN' R , N' is any one of the four bases A, T, C, and G, N' and N are complementary bases, R represents the number of bases, and the value of R is an integer between 15 and 19.

[0041] Preferably, in S5, the annealing procedure of the mixed annealing assembly is: incubation at 94°C for 5 min, incubation at 65°C for 30 min, incubation at 50°C for 30 min, incubation at 37°C for 30 min, incubation at 25°C for 30 min, and incubation at 4°C for more than 2 h.

[0042] The present invention also provides an application of a composition of the OX40 bivalent nucleic acid aptamer and CpG prepared by the preparation method of the present invention in the preparation of a drug for tumor immunotherapy.

[0043] Preferably, the tumor is at least one of andrological tumors, gynecological tumors, respiratory system tumors, digestive system tumors, hematological tumors, urological system tumors, bone marrow tumors, neurological tumors, dermatological tumors, general surgical tumors and ENT tumors.

[0044] Preferably, the male tumor is at least one of prostate cancer, penile cancer, testicular tumor and male urethral cancer.

[0045] Preferably, the gynecological tumor is at least one of ovarian cancer, cervical cancer, endometrial cancer, uterine fibroids, vulvar cancer and malignant hydatidiform mole.

[0046] Preferably, the respiratory system tumor is at least one of lung cancer, non-small cell lung cancer, small cell lung cancer, nasopharyngeal carcinoma, tracheal tumor, lung cancer metastasis, inflammatory pseudotumor and radiation-induced lung cancer.

[0047] Preferably, the digestive system tumor is at least one of liver cancer, gastric cancer, colorectal cancer, gallbladder cancer, esophageal cancer, rectal cancer, pancreatic cancer and colon cancer.

[0048] Preferably, the hematological tumor is at least one of leukemia, lymphoma, lymphosarcoma and multiple myeloma.

[0049] Preferably, the cancer is at least one of renal cancer, bladder cancer and urinary cancer.

[0050] Preferably, the bone marrow tumor is at least one of giant cell tumor of bone, osteochondroma and osteosarcoma.

[0051] Preferably, the neurological tumor is at least one of a brain tumor, a meningioma, a brain tuberculoma, a pituitary tumor, a neuroblastoma, a glioblastoma and a glioma.

[0052] Preferably, the dermatological tumor is skin cancer and / or melanoma.

[0053] Preferably, the general surgical tumor is at least one of breast cancer, lipoma, thyroid cancer and thyroid tumor.

[0054] Preferably, the ENT tumor is at least one of oral cancer, tongue cancer, laryngeal cancer, middle ear cancer, gingival cancer and orbital tumor.

[0055] Preferably, during application, the composition is administered by at least one of tumor administration, intravenous administration and intraperitoneal administration.

[0056] Preferably, during application, the single dosage of the composition is biR OX40 5.75~23μg / mouse, CpG 25~100μg / mouse.

[0057] Preferably, during application, the single dosage of the composition is biR OX40 5.75μg / mouse, CpG 25μg / mouse.

[0058] Beneficial effects of the present invention:

[0059] 1) The OX40 bivalent nucleic acid aptamer in the composition of the OX40 bivalent nucleic acid aptamer and CpG of the present invention optimizes the original OX40 aptamer based on the principle of base complementary pairing and the characteristics of flexible functional elements. The assembled OX40 bivalent aptamer has higher stability and lower cost than antibodies while retaining the functional structure of the aptamer. Then, the composition is made into a composition with CpG and applied to tumor immunotherapy. The OX40 bivalent aptamer can specifically recognize and bind to the OX40 receptor on the surface of tumor cells. One bivalent aptamer molecule can simultaneously recognize and bind to two OX40 receptor molecules, stimulate the OX40 / OX40L signaling pathway, have an immune-stimulating effect, promote the proliferation of effector T cells, the generation and maintenance of memory T cells, and inhibit the proliferation of Tregs; CpG, as an immune adjuvant, can promote the activation of T cells by secreting cytokines, increase the expression of OX40 on T cells, and maintain the immune-stimulating function mediated by OX40. The combination of the two, as a dual immune agonist, has a synergistic anti-tumor immune effect of "1+1>2", effectively achieving specific immune activation and clearance of tumor cells;

[0060] 2) The OX40 bivalent nucleic acid aptamer and CpG composition of the present invention is applied to tumor immunotherapy, and has the ability to inhibit tumor recurrence. At the same time, it also shows a certain universality in the treatment of other tumor models. Compared with the preparation method of traditional tumor immunotherapy drugs, the preparation method of the OX40 bivalent nucleic acid aptamer and CpG composition of the present invention has the advantages of simple preparation, small batch difference, low immunogenicity, convenient storage and transportation, and inducing systemic anti-tumor immune response. It can improve the treatment effect, reduce the treatment cost, and reduce the economic burden of patients. It has the value of promotion and application in the field of biomaterial technology. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 is a design flow chart; wherein (A) is the in vitro transcription of RNA-OX40a and biR OX40 Schematic diagram of the self-assembly structure; (B) is the OX40 bivalent aptamer biR OX40 Design drawings;

[0062] Figure 2 For biR OX40 In vitro assembly and characterization; wherein, (A) is a diagram of the transcription analysis of RNA-OX40a using 20% ​​denaturing polyacrylamide gel electrophoresis (dPAGE) in 1×TBE buffer at 55°C; (B) is a diagram of the transcription analysis of RNA-OX40a using 20% ​​denaturing polyacrylamide gel electrophoresis (dPAGE) in 1×TAE / Mg 2+ The biR was analyzed by 8% non-denaturing polyacrylamide gel electrophoresis (nPAGE) in the buffer.OX40 (C) is the result of atomic force microscopy (AFM) characterization of biR OX40 The morphology diagram;

[0063] Figure 3 For biR OX40 and CpG mixture for in situ treatment of lymphoma; (A) is a flowchart of mouse treatment; (B) is a tumor growth curve; each broken line represents a mouse. Tr: treated end tumor; NT: untreated end tumor; orange arrow: mouse injection date; (C) is the solvent group and biR OX40 +Photos of mice in the CpG group, with red arrows indicating the treatment site; (D) is a survival curve of mice, compared with the solvent group, ***p<0.001;

[0064] Figure 4 For biR OX40 The results of in vivo toxicity analysis of mice after using the mixed solution with CpG; (A) is the result of the weight of mice in different dose groups (n=6); (B) is the result of pathological analysis of the main organs of mice in the treatment group by H&E staining (n=3), scale bar: 200μm;

[0065] Figure 5 The results of the effect of in situ tumor treatment on intratumoral T lymphocytes are shown in the figure; wherein, (A) is a flow chart of T cell detection; (B) is a result diagram of flow cytometry analysis of the number of intratumoral CD8+T cells at the treatment end; (C) is a result diagram of flow cytometry analysis of the number of intratumoral Treg cells at the treatment end; (D) is a result diagram of ELISpot analysis of the secretion of IFN-γ by intratumoral lymphocytes at the treatment end; (E) is a result diagram of flow cytometry analysis of the number of intratumoral CD8+T cells at the untreated end; (F) is a result diagram of ELISpot analysis of the secretion of IFN-γ by intratumoral lymphocytes at the untreated end; for B, C and E, the results are expressed as mean ± standard deviation (n=3), *p<0.05, **p<0.01, ***p<0.001; for D and F, the results are expressed as mean ± standard deviation (n=6), *p<0.05, **p<0.01, ***p<0.001;

[0066] Figure 6The results of the effects of in situ tumor treatment on intratumoral T lymphocytes and tumor tissues are shown in the figure; (A) shows the upregulation of OX40 expression in CD8+T cells induced by CpG treatment; (B) shows the infiltration of CD8+T cells in the tumor by immunofluorescence section analysis, scale bar: 100 μm, and the quantitative analysis was completed by ImageJ software; (C) shows the hematoxylin-eosin (H&E) staining results of tumor tissues in different groups (n=3), scale bar: 100 μm; for A and B, the results are expressed as mean ± standard deviation (n=3); for B, *** indicates p<0.001 compared with the solvent group;

[0067] Figure 7 For biR OX40 Figure 2 shows the effect of combined use of HER2 and CpG on immune memory ability; (A) is a flow chart of T cell detection; (B) is the effect of the drug on CD4+ memory T cells; (C) is the effect of the drug on CD8+ memory T cells; (D) is the effect of the drug on regulatory T cells (Tregs); (E) is the result of ELISpot analysis of IFN-γ secretion by spleen cells from treated mice; (F) is the result of tumor recurrence resistance test in cured mice, blue line: untreated mice (n=5), red line: mice that had been treated with biR 90 days before subcutaneous implantation of A20 and 4T1 cells OX40 + CpG-cured A20 lymphoma mice (n=5); for BD, the results are expressed as mean ± SD (n=3), *p<0.05, **p<0.01, ***p<0.001; for E, the results are expressed as mean ± SD (n=6), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001;

[0068] Figure 8 To analyze biR by flow cytometry OX40 The result diagram of the synergistic effect of combined use of AMP and CpG on immune memory precursor T cells; wherein (A) is immune memory T cells; (B) is the recognition region of CD4+ memory T cells; (C) is the recognition region of CD8+ memory T cells;

[0069] Fig. 9 For biR OX40 The result diagram of the synergistic effect of dapoxetine and CpG on MPECs; (A) is MPEC; (B) is the recognition region of CD4+MPEC; (C) is the recognition region of CD8+MPEC; (D) is the effect on CD4+MPEC; (E) is the effect on CD8+MPEC; the results are expressed as mean ± standard deviation (n=3), *p<0.05, **p<0.01, ***p<0.001;

[0070] Fig.10 The results of analyzing the Treg cell population in the spleen by flow cytometry are shown in Figure 1. (A) is the immune memory T cell; (B) is the recognition area of ​​the Treg cell. DETAILED DESCRIPTION

[0071] The following will describe the embodiments of the present invention with reference to the preferred embodiments, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be understood that the preferred embodiments are only for illustrating the present invention, not for limiting the scope of protection of the present invention.

[0072] The present invention aims to provide a composition, preparation method and application of OX40 bivalent nucleic acid aptamer and CpG to solve the problems of high cost and strong immunogenicity of existing OX40 antibody agonist drugs, and explore new applications in the treatment of lymphoma and other tumors.

[0073] The composition of OX40 bivalent nucleic acid aptamer and CpG comprises a mixed solution of OX40 bivalent nucleic acid aptamer and CpG agonist.

[0074] In some embodiments, the OX40 bivalent nucleic acid aptamer is biR OX40 .

[0075] In some embodiments, the OX40 bivalent aptamer is self-assembled by RNA-OX40a and a DNA scaffold, and the nucleotide sequence of RNA-OX40a is shown in SEQ ID NO:6.

[0076] Among them, SEQ ID NO:6 single-stranded nucleic acid:

[0077] GGGAGGACGAUGCGGCAGUCUGCAUCGUAGGAAUCGCCACCGUAUACUUUCCCACNR, N is any one of the four bases A, T, C, and G, and R represents the number of bases, and the value of R is 19.

[0078] CpG is a potent agonist of Toll-like receptor 9 (TLR9) and is often used as an immune adjuvant due to its strong immunostimulatory ability.

[0079] The combination of OX40 bivalent aptamer drug and CpG for tumor immunotherapy has good therapeutic effect in animal experiments.

[0080] In some embodiments, the method for preparing a composition of OX40 bivalent nucleic acid aptamer and CpG comprises the following steps:

[0081] S1, mixing RNA-OX40a-T and RNA-OX40a-B and annealing them to obtain a first mixed solution;

[0082] S2, transcribing the first mixed solution under the first temperature condition to obtain a second mixed solution;

[0083] S3, purifying the second mixed solution by gel electrophoresis to obtain a third mixed solution;

[0084] S4, purifying the third mixed solution by ethanol precipitation, and vacuum drying to obtain RNA-OX40a;

[0085] S5, RNA-OX40a was mixed with DNA scaffold for annealing and assembly to obtain biR OX40 ;

[0086] S6、BiR OX40 The aptamer was mixed with a buffer solution containing a CpG agonist to obtain a mixed solution of the OX40 bivalent nucleic acid aptamer and the CpG agonist.

[0087] The CpG agonist is CpG 1826. The sequence of CpG 1826 is shown in SEQ ID NO:5.

[0088] SEQ ID NO:5: T*C*C*A*T*G*A*C*G*T*T*C*C*T*G*A*C*G*T*T, * indicates the phosphorothioate backbone.

[0089] In some embodiments, in S1, RNA-OX40a-T and RNA-OX40a-B form a double-stranded template nucleic acid, which anneals to form a specific secondary structure.

[0090] In some embodiments, in S6, RNA-OX40a is a single-stranded nucleic acid, and the RNA-OX40a is mixed with a DNA scaffold and annealed to form a specific secondary structure.

[0091] In some embodiments, in S1, the nucleotide sequence of RNA-OX40a-T is as shown in SEQ ID NO:7.

[0092] In some embodiments, in S2, the nucleotide sequence of RNA-OX40a-B is as shown in SEQ ID NO:8.

[0093] Among them, SEQ ID NO:7 single-stranded nucleic acid:

[0094] TTCTAATACGACTCACTATAGGGAGGACGATGCGGCAGTCTGCATCGTAGGAATCGCCACCGTATACTTTCCCACNR, N is any one of the four bases A, T, C, and G, R represents the number of bases, and the value of R is an integer between 15 and 19;

[0095] SEQ ID NO:8 Single-stranded nucleic acid:

[0096] N'RGTGGGAAAGTATACGGTGGCGATTCCTACGATGCAGACTGCCGCATCGTCCTCCCTATAGTGAGTCGTATTAGAA, N' and N are complementary bases, R represents the number of bases, and the value of R is an integer between 15 and 19.

[0097] In some embodiments, in S1, the ratio of RNA-OX40a-T to RNA-OX40a-B is 1:1, and the dosage is 1 μg.

[0098] In some embodiments, in S1, the annealing buffer used in the mixed annealing treatment is DEPC water.

[0099] In some embodiments, in S1, the procedure of the mixed annealing treatment is: incubation at 95°C for 5 min, incubation at 65°C for 30 min, incubation at 50°C for 30 min, incubation at 37°C for 30 min, incubation at 25°C for 30 min, and incubation at 4°C for more than 2 h.

[0100] In some embodiments, in S2, the first mixed solution is transcribed under a first temperature condition using a transcription kit.

[0101] In some embodiments, in S2, the first temperature is 37°C.

[0102] In some embodiments, in S2, the time for transcribing the first mixed solution under the first temperature condition is 16 hours.

[0103] In some embodiments, the transcription kit is selected from T7 RiboMAX TM Express kit, buffer is T7RiboMAX TM Express 2×Buffer. T7 RNA polymerase usage is 2μL.

[0104] In some embodiments, in S5, the ratio of RNA-OX40a to DNA scaffold is 2.8-3.2:1.

[0105] In some embodiments, in S5, the DNA scaffold is DNA-OX40a-S.

[0106] The nucleotide sequence of DNA-OX40a-S (41 nt) is shown in SEQ ID NO:9.

[0107] Among them, SEQ ID NO:9 single-stranded nucleic acid: N'RTTTN'R, N' is any one of the four bases A, T, C, and G, N' and N are complementary bases, R represents the number of bases, and the value of R is an integer between 15 and 19.

[0108] In some embodiments, in S5, the annealing procedure of the mixed annealing assembly is: incubation at 94°C for 5 min, incubation at 65°C for 30 min, incubation at 50°C for 30 min, incubation at 37°C for 30 min, incubation at 25°C for 30 min, and incubation at 4°C for more than 2 h.

[0109] In some embodiments, there is also provided the use of a composition of OX40 bivalent nucleic acid aptamer and CpG prepared by the preparation method in any of the above embodiments in the preparation of drugs for tumor immunotherapy.

[0110] In some embodiments, the tumor is at least one of andrological tumors, gynecological tumors, respiratory system tumors, digestive system tumors, hematological tumors, urological tumors, bone marrow tumors, neurological tumors, dermatological tumors, general surgical tumors, and ENT tumors;

[0111] Male tumors are at least one of prostate cancer, penile cancer, testicular tumors, and male urethral cancer;

[0112] Gynecological tumors are at least one of ovarian cancer, cervical cancer, endometrial cancer, uterine fibroids, vulvar cancer, and malignant hydatidiform mole;

[0113] The respiratory system tumor is at least one of lung cancer, non-small cell lung cancer, small cell lung cancer, nasopharyngeal carcinoma, tracheal tumor, lung cancer metastasis, inflammatory pseudotumor and radiation-induced lung cancer;

[0114] The digestive system tumor is at least one of liver cancer, stomach cancer, colorectal cancer, gallbladder cancer, esophageal cancer, rectal cancer, pancreatic cancer and colon cancer;

[0115] Hematological tumors are at least one of leukemia, lymphoma, lymphosarcoma and multiple myeloma;

[0116] at least one of kidney cancer, bladder cancer, and urinary cancer;

[0117] The bone marrow tumor is at least one of giant cell tumor of bone, osteochondroma, and osteosarcoma;

[0118] The neurological tumor is at least one of brain tumor, meningioma, brain tuberculoma, pituitary tumor, neuroblastoma, glioblastoma and glioma;

[0119] Dermatological tumors are skin cancer and / or melanoma;

[0120] General surgery tumors are at least one of breast cancer, lipoma, thyroid cancer, and thyroid tumor;

[0121] The ENT tumor is at least one of oral cancer, tongue cancer, laryngeal cancer, middle ear cancer, gingival cancer and orbital tumor.

[0122] Wherein, during the application process, the composition is administered by at least one of tumor administration, intravenous administration and intraperitoneal administration. During the application process, the single administration dose of the composition is biR OX40 5.75~23μg / mouse, CpG25~100μg / mouse.

[0123] In order to make the technical problems, technical solutions and beneficial effects solved by the present application clearer, the preparation method of the composition of the OX40 bivalent nucleic acid aptamer and CpG of the present invention will be further described in detail below in conjunction with specific embodiments and drawings. Obviously, the specific embodiments described are only part of the embodiments of the present application, rather than all of the embodiments. The following description of at least one exemplary embodiment is actually only illustrative and is by no means intended to limit the present application and its application. Based on the specific embodiments in the present application, all other embodiments obtained by ordinary technicians in the art without creative work are within the scope of protection of the present application.

[0124] If no specific techniques or conditions are specified in the specific embodiments, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0125] Example 1 Sequence design and optimization

[0126] like Figure 1 As shown in B, (1) based on the base complementary pairing principle, base stacking force, characteristics of flexible functional elements and other factors, the base AC connection is added to the 3' of the OX40 aptamer, and the tail ACUCGCUGA CGAU CCGACA is connected. The tail is complementary to the DNA scaffold and is used to construct the OX40 bivalent aptamer. The OX40 aptamer variant is named RNA-OX40a. The nucleotide sequence of RNA-OX40a is shown in SEQ ID NO: 1. The above optimization method not only retains the function of the OX40 aptamer itself and the affinity with the OX40 receptor, but also further improves the structural stability of the RNA aptamer, thereby reducing the difficulty of in vitro transcription.

[0127] The DNA scaffold consists of two parts: two DNA single strands complementary to the tail of RNA-OX40a and a connecting part in the middle, the connecting part is TTT. The DNA scaffold is named DNA-OX40-S. The nucleotide sequence of DNA-OX40-S is shown in SEQ ID NO: 2. This design retains good flexibility while being more economical.

[0128] Among them, SEQ ID NO: 1 single-stranded nucleic acid: GGGAGGACGAUGCGGCAGUCUGCAUCGUAGGAAUCGCC ACCGUAUACUUUCCCACACUCGCUGACGAUCCGACA (74 nt).

[0129] SEQ ID NO: 2 Single-stranded nucleic acid: TGTCGGATCGTCAGCGAGTTTTTGTCGGATCGTCAGCGAGT (41

[0130] nt).

[0131] (2) Figure 1 As shown in A, the DNA strand with the same sequence as RNA-OX40a is the sense strand. The T7 promoter sequence TAATACGACTCACTATA is added to the 5' end of the sense strand to obtain RNA-OX40a-T. The nucleotide sequence of RNA-OX40a-T is shown in SEQ ID NO:3. Subsequently, the complementary antisense strand RNA-OX40a-B is designed according to the sense strand sequence, and a double-stranded DNA template is synthesized. Using the T7 transcription kit, NTP is used as a substrate to synthesize RNA-OX40a from the first G downstream of the T7 promoter. The other is a complementary strand (or antisense strand, non-template strand), named RNA-OX40a-B, and the nucleotide sequence of RNA-OX40a-B is shown in SEQ ID NO:4.

[0132] SEQ ID NO: 3 single-stranded nucleic acid: TTCTAATACGACTCACTATAGGGAGGACGATGCGGCAGTCTGC ATCGTAGGAATCGCCACCGTATACTTTCCCACACTCGCTGACGATCCGACA (94nt).

[0133] SEQ ID NO: 4 single-stranded nucleic acid: TGTCGGATCGTCAGCGAGTGTGGGAAAGTATACGGTGGCGATT CCTACGATGCAGACTGCCGCATCGTCCTCCCTATAGTGAGTCGTATTAGAA (94nt).

[0134] Example 2OX40 bivalent nucleic acid aptamer biR OX40

[0135] OX40 bivalent nucleic acid aptamer biR OX40 The preparation method comprises the following steps:

[0136] S1, RNA-OX40a-T and RNA-OX40a-B are mixed and annealed to obtain a first mixed solution, which specifically includes:

[0137] RNA-OX40a-T and RNA-OX40a-B were mixed at a molar ratio of 1:1, DEPC water was added, and annealing treatment was performed to form a secondary structure to synthesize a double-stranded DNA template. The annealing treatment procedure was: incubation at 94°C for 5 min, incubation at 65°C for 30 min, incubation at 50°C for 30 min, incubation at 37°C for 30 min, incubation at 25°C for 30 min, and incubation at 4°C for 2 h;

[0138] S2. Using a transcription kit, transcribing under a first temperature condition to obtain a second mixed solution, specifically comprising:

[0139] Add buffer and T7 RNA polymerase to the first mixed solution obtained in S1 to obtain a mixed solution, then place the mixed solution in a 37°C constant temperature metal bath for reaction for 16 hours, and centrifuge for standby use after the reaction; then add 2 μL of DNase I to the solution after centrifugation, mix well with a pipette tip, and react at 37°C for half an hour to remove the template DNA, and obtain a second mixed solution after the reaction;

[0140] The buffer is T7 RiboMAX TM Express 2×Buffer;

[0141] S3, purifying the second mixed solution by gel electrophoresis to obtain a third mixed solution, specifically comprising:

[0142] The second mixed solution obtained in S2 is purified by 20% denaturing polyacrylamide gel electrophoresis (dPAGE); the temperature is 55° C., the buffer is 1×TBE, and the third mixed solution is obtained after gel recovery;

[0143] S4, concentrating the third mixed solution, ethanol purification, and vacuum drying to obtain RNA-OX40a, specifically comprising:

[0144] The third mixed solution obtained in S3 was extracted with n-butanol to concentrate the RNA aqueous solution to about 800 μL, and the RNA was purified by ethanol precipitation, and vacuum-dried at 37°C until a small amount of white solid appeared to obtain RNA-OX40a. An appropriate amount of DEPC water was added to fully dissolve the RNA solid powder;

[0145] S5, the RNA-OX40a obtained in S4 and the DNA scaffold DNA-OX40a-S designed in Example 1 were mixed at a molar ratio of 3.0:1.0, and annealed and assembled to obtain the OX40 bivalent nucleic acid aptamer biR OX40 ; Among them, the annealing program is: incubation at 95℃ for 5min, incubation at 65℃ for 30min, incubation at 50℃ for 30min, incubation at 37℃ for 30min, incubation at 25℃ for 30min, and incubation at 4℃ for 2h.

[0146] Example 3 Composition of OX40 bivalent nucleic acid aptamer and CpG

[0147] The preparation method of the composition of OX40 bivalent nucleic acid aptamer and CpG comprises the following steps:

[0148] The OX40 bivalent nucleic acid aptamer biR OX40 Mixing with a buffer containing a CpG1826 agonist to obtain a mixed solution of OX40 bivalent nucleic acid aptamer and CpG1826;

[0149] Among them, the CpG 1826 sequence is shown in SEQ ID NO:5.

[0150] SEQ ID NO:5: T*C*C*A*T*G*A*C*G*T*T*C*C*T*G*A*C*G*T*T, * is a phosphorothioate backbone

[0151] Detection and analysis

[0152] 1) 20% denaturing polyacrylamide gel electrophoresis to verify RNA-OX40a transcription

[0153] The purity of the RNA-OX40a aptamer prepared in S4 of Example 2 was verified using 20% ​​denaturing PAGE.

[0154] The specific operation is as follows: take 20% denatured polyacrylamide solution (20 mL), coagulant TEMED (15 μL) and 10% After APS (180μL) is mixed, quickly pour the gel into the gap between the two glass plates; insert the comb and wait for the gel to solidify; rotate the fixing buckle in the opposite direction and take out the assembled glass plate; slowly pull out the comb and quickly pour first-level water into the gel hole; after gelation, immediately pull out the comb and rinse the loading hole, and use 1×TBE buffer for gel electrophoresis; take 1μg of the RNA-OX40a aptamer prepared in S4 of Example 2, add DEPC water to 10μL and 70% glycerol (DEPC water configuration) 5μL; add each sample to the gel well of 20% denatured polyacrylamide gel; use 25-500bp DNA Marker as a band control; where the electrophoresis conditions are: electrophoresis time is 3h, voltage is 550V, temperature is 55℃; Stains-All stains the gel for 5min and fades under light; use a Canon scanner to record the gel image and grayscale processing and analysis. The results are as follows Figure 2 (A) shown.

[0155] from Figure 2 As shown in (A), the target RNA-OX40a obtained by transcription has a clear and thick band, which proves that the target RNA can be obtained by T7 transcription with a high yield.

[0156] 2) Characterization of OX40 bivalent nucleic acid aptamer (biR OX40 )

[0157] The biR assembled in Example 2 was characterized by 8% native PAGE. OX40 .

[0158] The specific operation is as follows: 4 mL of 40% polyacrylamide / methylenebisacrylamide solution, 2 mL of 10×TAE / Mg 2+ Buffer, 14 mL of first-grade water, 20 μL of TEMED and 10% 200 μL of APS were mixed and poured into the gap between the glass plates; after gelation, the comb was immediately removed and the sample wells were rinsed, and 1×TAE / Mg 2+ Buffer was used for gel running; the biR OX40

[0159] 1 μg was added with 70% glycerol (5 μL, prepared with DEPC water), the tip was mixed, centrifuged, and a 25-500 bp DNA marker was used as a band control; the electrophoresis conditions were: voltage 220V, temperature 4°C, time 2.5h, Stains-All stained gel for 5min, light fading; the gel image was recorded using a Canon scanner and grayscale processing was analyzed. The results are shown in Figure 2 (B) shown.

[0160] from Figure 2 (B) Analysis shows that under the condition of a stoichiometric ratio of RNA-OX40a to DNA-OX40-S of 1:1, three structures were assembled, which appeared as three different bands, corresponding to DNA-OX40-S (the first band), the complex formed by RNA-OX40a and DNA scaffold (DNA-OX40-S) (1:1 molar ratio) (the second band), and the complex (2:1 molar ratio) biR OX40 (the third band), thus proving that RNA aptamers and DNA scaffolds can form complexes at molar ratios of 1:1 and 2:1. In the range of molar ratios of 2.8 to 3.2:1, complexes with a molar ratio of mainly 2:1 are formed.

[0161] 3) Atomic force microscopy characterization of OX40 bivalent nucleic acid aptamer (biR OX40 )

[0162] The specific operations are:

[0163] (1) Sample preparation: According to the scanning concentration requirements, 3 μM of the OX40 bivalent aptamer (biR OX40 ) was diluted 20 times with DEPC water as the sample to be tested and set aside; poly-lysine solution (5 μg / μL, 20 μL) was dripped on the mica surface; incubated for 10 minutes, and then the solution was blown dry with nitrogen gas and rinsed twice with primary water; 5 μL of the sample to be tested diluted 20 times was taken and dripped on the mica surface and incubated for 5 minutes; finally, 20 μL of 1×TAE / Mg 2+ Buffer solution is placed on the surface of the sample to be tested;

[0164] (2) Characterization: Computer, controller and light source, open "Nanoscope 9.2" software, select liquid phase mode in the software interface and select liquid phase scanning needle tip. Fix the needle tip on the probe clamp and add 20μL 1×TAE / Mg 2+ Buffer, flip the probe clip and place it in the Head. Move the reflector so that the SUM value is about 6, and adjust the vertical and horizontal values ​​in the four quadrants to be within ±0.5. Place the iron sheet carrying the mica sheet of the sample to be tested on the scanning tube, find the position of the mica surface and the needle tip under the lens, adjust the direction button to make the needle tip close to the mica surface, and stop when the needle tip is almost clear. Set the scanning parameters on the computer software, set the peak force freq value to 2kHz, and insert the needle to scan. The scanning range is gradually increased from 10nm to 1μm, and samples / line is set to 512, which makes the scan clearer. According to the scanned image results, you can zoom in on the scan and save the required results. The results are as follows Figure 2 (C) shown.

[0165] from Figure 2 From the analysis in (C), we can see that biR OX40 It presents a single linear structure with a length of about 10 nm and a height of about 1.5 nm, which is consistent with the theoretical size, thus proving the successful formation of the divalent structure.

[0166] 4) Anti-tumor effect of the combination of OX40 bivalent nucleic acid aptamer and CpG and its effect on the survival rate of mice

[0167] The specific operations are:

[0168] (1) A mixture of the OX40 bivalent aptamer prepared in Example 3 and CpG1826 (Toll-like receptor agonist) was taken and grouped according to the dosage. The specific groups are shown in Table 1.

[0169] Table 1 BiR in different dose groups OX40 and the specific amount of CpG

[0170]

[0171]

[0172] (2) Figure 3 As shown in (A), A20 lymphoma cells (5×10 6 When the maximum diameter of the tumor reached 0.5 to 0.7 cm (usually 5 to 6 days after inoculation), CpG1826 agonist and OX40 bivalent aptamer were injected into the left tumor edge of the mouse in a volume of 50 μL. Injection was performed into one tumor site every other day for a total of three injections. The tumor size on both sides of the modeling mice was monitored with a vernier caliper every 2 to 3 days, and the length and width of the tumor and the weight of the mouse were recorded.

[0173] (3) According to the animal experiment guidelines, when the maximum volume of the tumor exceeds 2 cm 3 The mice were euthanized at 1:10 pm. The survival rate of each group of mice was counted and a survival curve was drawn. All mice with tumors on both sides of the abdomen were included in the experiment. Figure 3 (B) Figure 3 (C) and Figure 3 (D) as shown.

[0174] from Figure 3(B) The analysis shows that when the mixture of the OX40 bivalent aptamer and the CpG1826 agonist prepared in Example 3 was used to treat tumor mice, the tumors on both sides of all treated mice gradually and completely disappeared. The results show that the combination of drugs has a significant therapeutic effect in the treatment of mouse lymphoma. In the low-dose group, mice showed a decrease in tumor volume after the second dose. Throughout the treatment process, the tumor volume of all mice was well controlled, and the tumor regression rates at the treatment end and the non-treatment end were comparable. Based on the above results, biROX40 of 5.75μg and CpG of 25μg are the optimal doses for therapeutic effects.

[0175] from Figure 3 It can be seen from the analysis in (C) that when the mixture of the OX40 bivalent aptamer and the CpG1826 agonist prepared in Example 3 is used to treat tumor-bearing mice, the tumors at both the treated and non-treated ends of the mice can be completely regressed.

[0176] from Figure 3 The analysis in (D) shows that within 40 days, the survival rate of mice in the lymphoma model treated with the mixture of OX40 bivalent aptamer prepared in Example 3 and CpG1826 agonist can reach 100%. OX40 The survival rate of lymphoma mice in the +CpG group was significantly improved (p<0.001).

[0177] 5) H&E staining to investigate the safety of OX40 bivalent aptamer combined with CpG

[0178] Collect the hearts, livers, spleens, lungs, and kidneys of the surviving mice in 4) and fix them with 4% paraformaldehyde. Dehydrate with gradient ethanol and treat with xylene to make them transparent. Embed the mouse organs in paraffin. Use a tissue slicer to cut 3μM paraffin sections and attach them flat on glass slides. Bake at 61℃ for more than 6h. Wash, stain, and rinse to remove excess dye, add neutral gum to the tissue, cover with a coverslip, and lay flat to dry; take pictures under an inverted microscope to record the tissue structure of each organ. The results are as follows Figure 4 (B) shown.

[0179] in, Figure 4 (A) is the body weight of mice after treatment with different dose groups. Figure 4 As can be seen from the analysis in (A), the weight of mice increased steadily, indicating that the drug did not affect the growth of mice.

[0180] from Figure 4 As can be seen from the H&E sections in (B), there was no significant difference in cell morphology and tissue structure between the drug-treated group and the vehicle group. OX40 It has good biosafety compared to CpG and has no obvious systemic toxic side effects.

[0181] 6) Effects of OX40 bivalent aptamer combined with CpG on tumor infiltrating lymphocytes

[0182] The specific operations are:

[0183] (1) Flow cytometry analysis: Figure 5 As shown in A, on the 4th day after the third administration of mice (the dosage is shown in Table 1), the mouse tumor was removed, washed with an appropriate amount of Hank's solution, and the mouse tumor was cut into pieces. Grind and sieve to collect, centrifuge at a speed of 1300rpm for 5min, and then resuspend the precipitate with RPMI-1640, filter and centrifuge to collect cells. Add 1× mouse lymphocyte extract and RPMI-1640 to mix, centrifuge in a horizontal centrifuge at a speed of 800rpm for 30min. Collect the culture medium layer and lymphocyte layer after stratification, discard the precipitate, add 10mL RPMI-1640, wash the cells, centrifuge at a speed of 1300rpm for 5min. Repeat the steps of adding 10mL RPMI-1640 and the following steps. After centrifugation, resuspend the cell precipitate in 2mL PBS, add the antibody and incubate at room temperature in the dark for 30min, continue washing after incubation, centrifuge, resuspend in PBS, and detect the cell sample by flow cytometry.

[0184] (2) ELISPOT assay: Prepare a suspension of mouse tumor-infiltrating lymphocytes and adjust the cell concentration to 106 cells / mL. Activate the pre-coated plate with culture medium and add the cell suspension to the experimental wells. Add PMA positive stimulator working solution to the positive control well and culture medium to the remaining wells. Incubate in a 37°C, 5% CO2 incubator for 24 hours. After completion, add deionized water, place in a 4°C refrigerator for 10 minutes, then wash the plate. Add biotin-labeled antibody to detect the antibody and incubate, then wash the plate. Add enzyme-linked avidin working solution, incubate at 37°C for 1 hour, then wash the plate. Add the freshly prepared AEC color development solution and let stand at 37°C in the dark for about 20 minutes. Add tap water to stop color development. Finally, count the ELISPOT plate spots and record various parameters of the spots.

[0185] (3) Immunofluorescence analysis of CD8+ T cell infiltration in tumors: On the 4th day after the third administration of the mice, the tumor was removed and cut into 0.5 cm 3 The size was fixed by immersion in 4% paraformaldehyde solution. Subsequent antibody staining service was provided by Wuhan Saiweier Biotechnology Co., Ltd. The received immunofluorescence sections were photographed using a fluorescence microscope. Three areas were photographed for each section. CD8+T cells were counted and analyzed using ImageJ 1.8.0.

[0186] (4) HE staining to investigate the effect of killing tumor cells in vivo: The mouse tumors on the 8th day after the end of treatment were sliced ​​and stained with H&E, and fixed with 4% paraformaldehyde. Dehydrated with ethanol gradient and treated with xylene to make it transparent. Embed mouse organs with paraffin. Use a tissue slicer to cut 3μM paraffin sections and attach them flat on the glass slide. Bake at 61℃ for more than 6h. Wash, stain, rinse to remove excess dye, add neutral gum to the tissue, cover with a coverslip, and lay flat to dry; take pictures under an inverted microscope to record the tissue structure of each organ.

[0187] The results are as follows Figure 5 (BF) and Figure 6 (AC) shown.

[0188] from Figure 5 (B) Analysis of the number of CD8+T cells at the treatment end by flow cytometry showed that the combination of OX40 bivalent aptamer and CpG can significantly increase the number of CD8+T cells compared with the solvent group and the control group. The CpG control group can significantly increase the number of CD8+T cells compared with the solvent group.

[0189] from Figure 5 (C) Flow cytometry analysis of the number of Treg cells in the tumor at the treatment end showed that the combination of OX40 bivalent aptamer and CpG could significantly reduce the number of Treg cells compared with the solvent group and the control group.

[0190] from Figure 5 (D) Analysis of the number of IFN-γ secreted by intratumoral lymphocytes in the treatment group by ELISpot assay showed that the CpG control group had a significantly higher secretion rate than the solvent group and biR OX40 The group significantly enhanced IFN-γ secretion, while the combination of OX40 bivalent aptamer and CpG could enhance IFN-γ secretion compared with the solvent group.

[0191] from Figure 5 (E) Analysis of the number of CD8+T cells in untreated tumors by flow cytometry showed that the combination of OX40 bivalent aptamer and CpG significantly increased the number of CD8+T cells compared with the solvent group and the control group, while the CpG control group had no effect on the untreated tumors.

[0192] from Figure 5 (F) Analysis of the number of IFN-γ secreted by lymphocytes in the untreated tumor by ELISpot assay showed that the combination of OX40 bivalent aptamer and CpG could significantly enhance IFN-γ secretion compared with the solvent group and CpG control group. OX40 The CpG control group and the solvent group could significantly increase the secretion of IFN-γ, while the CpG control group had no significant enhancing effect on the secretion of IFN-γ.

[0193] from Figure 6 (B) The analysis of the infiltration of CD8+T cells in the tumor observed by immunofluorescence sections showed that the number of CD8+T cells in the tumor of the OX40 bivalent aptamer combined with CpG was greater than that of the solvent group, indicating that the OX40 bivalent aptamer and CpG can significantly increase the number of CD8+T cells.

[0194] Therefore, from Figure 5 (BF) and Figure 6 From the analysis in (B), we can see that when biR OX40 When presented to the immune system together with CpG, they produced a synergistic effect in immune-mediated anti-tumor activity. The combination of OX40 bivalent aptamer and CpG can significantly increase CD8+T cell proliferation, inhibit Tregs proliferation, and increase IFN-γ secretion in tumor cells in the treatment segment. At the same time, CpG alone can induce CD8+T cell proliferation and IFN-γ secretion in the treated tumor, but has no effect on the untreated tumor.

[0195] from Figure 6 (A) Analysis of OX40 expression in CD8+ T cells by flow cytometry showed that CpG enhanced the expression of OX40 on activated T cells, thereby promoting the biR OX40 Binding to T cells.

[0196] from Figure 6 (C) Hematoxylin-eosin (H&E) staining analysis of tumor tissues in different groups showed that when CpG or biR OX40 When used alone, it can only cause damage to the tumor at the treatment end; biR OX40 When used in combination with CpG, it can cause damage to tumors on both the treatment side and the non-treatment side.

[0197] 7) Effect of OX40 bivalent aptamer combined with CpG on immune memory

[0198] The specific operations are:

[0199] (1) Flow cytometry analysis: Figure 7As shown in A, on the 8th day after the third administration of mice (the dosage is shown in Table 1), the spleen of the mice was aseptically removed in the clean bench, placed in an appropriate amount of Hank's solution to wash away hair and blood, and remove fat and fascia. Cut the spleen of the mouse. Grind and sieve to collect, centrifuge at a speed of 1300rpm for 5min, then resuspend the precipitate with RPMI-1640, filter and centrifuge to collect cells. Add 1× mouse lymphocyte extract and RPMI-1640 to mix, centrifuge in a horizontal centrifuge at a speed of 800rpm for 30min. Collect the culture medium layer and lymphocyte layer after stratification, discard the precipitate, add 10mL RPMI-1640, wash the cells, centrifuge at a speed of 1300rpm for 5min. Repeat the steps after adding 10mL RPMI-1640 again. After centrifugation, the cell pellet was resuspended in 2 mL PBS, and the antibody was added and incubated at room temperature in the dark for 30 min. After incubation, the cell pellet was washed, centrifuged, resuspended in PBS, and the cell samples were detected by flow cytometry.

[0200] (2) ELISPOT assay: On the 8th day after the third administration of the mice, spleen cell suspension was obtained. A20 cells were collected. Counted separately, the cell concentration was adjusted, the pre-coated plate was activated with culture medium, and the cell suspension was added to the experimental wells. PMA positive stimulator working solution was added to the positive control well, and culture medium was added to the remaining wells. Incubate in a 37°C, 5% CO2 incubator for 24 hours. After completion, deionized water was added, the plate was placed in a 4°C refrigerator for 10 minutes, and then the plate was washed. Biotin-labeled antibody was added to detect the antibody and incubated, and then the plate was washed. Enzyme-linked avidin working solution was added, and the plate was washed after incubation at 37°C for 1 hour. The AEC color development solution was added and the plate was left to stand at 37°C in the dark for about 20 minutes. Tap water was added to stop the color development. Finally, the ELISPOT plate spots were counted and various parameters of the spots were recorded.

[0201] (3) Inhibition of lymphoma recurrence: The mice cured of A20 tumors by the combination of bivalent aptamers and CpG were kept for 90 days and then re-established subcutaneously. 6 A20 cells or 0.01×10 6 4T1 cells were implanted subcutaneously in two groups of mice. The tumor size on both sides of the animals was monitored with a vernier caliper every 2 to 3 days, and the length and width of the tumor were recorded.

[0202] The results are as follows Figure 7 (BF), Figure 8 , Fig. 9 and Fig.10 shown.

[0203] from Figure 7 (B) Figure 8 (B) Analysis of the number of CD4+ memory T cells by flow cytometry and Figure 7 (C) Figure 8(C) Flow cytometry analysis of the number of CD8+ memory cells showed that memory T cells were present in the spleen of mice about 20 days after tumor development and that the biR OX40 CD8+ central memory T cells (TCM) and effector memory T cells (TEM) subsets were significantly increased in treated mice, indicating that biR OX40 Potential role in enhancing immune response to cancer.

[0204] from Fig. 9 The analysis of CD4+MPEC and CD8+MPEC by flow cytometry showed that CD127 and KLRG1 were used as indicators to analyze the memory precursor effector T cells (MPEC, KLRG1 low CD127 hi During the period of infection resolution, the expression of KLRG1 on the surface of some effector T cells gradually decreases, while the expression of CD127 gradually increases. This process leads to the formation of memory precursor T cells. OX40 MPEC increased significantly in mice treated with biR OX40 May enhance the production of long-lived immune cells.

[0205] from Figure 7 (D) ELISpot assay for the number and Fig.10 Flow cytometry analysis of Treg cell populations in the spleen showed that the presence of CpG significantly reduced Tregs in the spleen, which may be related to the systemic immune stimulatory effect of CpG.

[0206] from Figure 7 (E) Analysis of the amount of IFN-γ secreted by spleen cells by ELISpot assay showed that when the spleen lymphocytes of treated mice were restimulated with A20 lymphoma cells, the secretion of IFN-γ increased significantly, and the secretion level was even higher than when CpG alone was present, indicating that biRNA-OX40 and CpG may work synergistically to enhance the immune response to cancer cells.

[0207] from Figure 7 (F) Analysis of cured mice tested for resistance to tumor recurrence showed that the cured mice were resistant to the formation of A20 tumors, but not to the growth and continued enlargement of 4T1 tumors. This result suggests that this immunotherapy strategy can establish long-term immune memory and effectively resist tumor recurrence.

[0208] In summary, the OX40 bivalent nucleic acid aptamer in the composition of the OX40 bivalent nucleic acid aptamer and CpG of the present invention optimizes the original OX40 aptamer based on the principle of base complementary pairing and the characteristics of flexible functional elements. The assembled OX40 bivalent aptamer has higher stability and lower cost than antibodies while retaining the functional structure of the aptamer. Then, it is made into a composition with CpG and applied to tumor immunotherapy. The OX40 bivalent aptamer can specifically recognize and bind to the OX40 receptor on the surface of tumor cells. One bivalent aptamer molecule can simultaneously recognize and bind to two OX40 receptor molecules, stimulate the OX40 / OX40L signaling pathway, have an immune-stimulating effect, promote the proliferation of effector T cells, the generation and maintenance of memory T cells, and inhibit the proliferation of Tregs; CpG, as an immune adjuvant, can promote the activation of T cells by secreting cytokines, increase the expression of OX40 on T cells, and maintain the immune-stimulating function mediated by OX40. The combination of the two, as dual immune agonists, has a synergistic anti-tumor immune effect of "1+1>2", effectively achieving specific immune activation and clearance of tumor cells.

[0209] The OX40 bivalent nucleic acid aptamer and CpG composition of the present invention is applied to tumor immunotherapy, and has the ability to inhibit tumor recurrence. At the same time, it also shows a certain universality in the treatment of other tumor models. Compared with the preparation method of traditional tumor immunotherapy drugs, the preparation method of the OX40 bivalent nucleic acid aptamer and CpG composition of the present invention has the advantages of simple preparation, small batch difference, low immunogenicity, convenient storage and transportation, and inducing systemic anti-tumor immune response. It can improve the treatment effect, reduce the treatment cost, and alleviate the economic burden of patients. It has the value of promotion and application in the field of biomaterial technology.

[0210] The above embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Any equivalent substitution or change made by a person skilled in the art based on the present invention is within the protection scope of the present invention.

Claims

1. A composition of OX40 bivalent nucleic acid aptamer and CpG, characterized in that: The composition comprises a mixed solution of OX40 bivalent nucleic acid aptamer and CpG agonist.

2. The composition of OX40 bivalent nucleic acid aptamer and CpG according to claim 1, characterized in that: The OX40 bivalent nucleic acid aptamer is biR OX40 ; And / or, the OX40 bivalent aptamer is obtained by self-assembly of RNA-OX40a and a DNA scaffold, and the nucleotide sequence of the RNA-OX40a is shown in SEQ ID NO:

6.

3. The method for preparing the composition of OX40 bivalent nucleic acid aptamer and CpG according to claim 1 or claim 2, characterized in that: The following steps are involved: S1, mixing RNA-OX40a-T and RNA-OX40a-B and annealing them to obtain a first mixed solution; S2, transcribing the first mixed solution under the first temperature condition to obtain a second mixed solution; S3, purifying the second mixed solution by gel electrophoresis to obtain a third mixed solution; S4, purifying the third mixed solution by ethanol precipitation, and vacuum drying to obtain RNA-OX40a; S5, RNA-OX40a was mixed with DNA scaffold for annealing and assembly to obtain biR OX40 ; S6、BiR OX40 The aptamer was mixed with a buffer solution containing a CpG agonist to obtain a mixed solution of the OX40 bivalent nucleic acid aptamer and the CpG agonist.

4. The method for preparing the composition of OX40 bivalent nucleic acid aptamer and CpG according to claim 3, characterized in that: In S1, RNA-OX40a-T and RNA-OX40a-B form a double-stranded template nucleic acid, which anneals to form a secondary structure; and / or, in S6, RNA-OX40a is a single-stranded nucleic acid, and the RNA-OX40a is mixed with the DNA scaffold and annealed to form a secondary structure; And / or, in said S1, the nucleotide sequence of RNA-OX40a-T is as shown in SEQ ID NO: 7; And / or, in S2, the nucleotide sequence of RNA-OX40a-B is as shown in SEQ ID NO:

8.

5. The method for preparing the composition of OX40 bivalent nucleic acid aptamer and CpG according to claim 3, characterized in that: In S1, the molar ratio of RNA-OX40a-T to RNA-OX40a-B is 1.0-1.1: 1.0; And / or, in S1, the annealing buffer used in the mixed annealing treatment is DEPC water; And / or, in S1, the procedure of the mixed annealing treatment is: incubation at 95°C for 5 min, incubation at 65°C for 30 min, incubation at 50°C for 30 min, incubation at 37°C for 30 min, incubation at 25°C for 30 min, and incubation at 4°C for more than 2 h.

6. The method for preparing the composition of OX40 bivalent nucleic acid aptamer and CpG according to claim 3, characterized in that: In S2, the first mixed solution is transcribed using a transcription kit under a first temperature condition; And / or, in S2, the first temperature is 37° C.; And / or, in S2, the time for transcribing the first mixed solution under the first temperature condition is 16 hours.

7. The method for preparing the composition of OX40 bivalent nucleic acid aptamer and CpG according to claim 6, characterized in that: The transcription kit is selected from the T7 RiboMAX™ Express kit, the buffer is RiboMAXTM Express T72× Buffer, and the amount of T7 RNA polymerase is 2 µL.

8. The method for preparing the composition of OX40 bivalent nucleic acid aptamer and CpG according to claim 3, characterized in that: In the S5, the molar ratio of RNA-OX40a to DNA scaffold is 2.8-3.2: 1; and / or, in said S5, the DNA scaffold is DNA-OX40a-S; And / or, in S5, the annealing program of the mixed annealing assembly is: incubation at 94°C for 5 min, incubation at 65°C for 30 min, incubation at 50°C for 30 min, incubation at 37°C for 30 min, incubation at 25°C for 30 min, and incubation at 4°C for more than 2 h.

9. An application of a composition of OX40 bivalent nucleic acid aptamer and CpG prepared by the preparation method according to any one of claims 3 to 8, characterized in that: The composition is used in preparing drugs for tumor immunotherapy.

10. The use according to claim 9, characterized in that: The tumor is at least one of andrological tumors, gynecological tumors, respiratory system tumors, digestive system tumors, hematological tumors, urological system tumors, bone marrow tumors, neurological tumors, dermatological tumors, general surgical tumors, and ENT tumors; The male tumor is at least one of prostate cancer, penile cancer, testicular tumor and male urethral cancer; The gynecological tumor is at least one of ovarian cancer, cervical cancer, endometrial cancer, uterine fibroids, vulvar cancer and malignant hydatidiform mole; The respiratory system tumor is at least one of lung cancer, non-small cell lung cancer, small cell lung cancer, nasopharyngeal carcinoma, tracheal tumor, lung cancer metastasis, inflammatory pseudotumor and radiation lung cancer; The digestive system tumor is at least one of liver cancer, stomach cancer, colorectal cancer, gallbladder cancer, esophageal cancer, rectal cancer, pancreatic cancer and colon cancer; The hematological tumor is at least one of leukemia, lymphoma, lymphosarcoma and multiple myeloma; At least one of renal cancer, bladder cancer and urinary cancer; The bone marrow tumor is at least one of giant cell tumor of bone, osteochondroma and osteosarcoma; The neurological tumor is at least one of a brain tumor, a meningioma, a brain tuberculoma, a pituitary tumor, a neuroblastoma, a glioblastoma and a brain glioma; The dermatological tumor is skin cancer and / or melanoma; The general surgical tumor is at least one of breast cancer, lipoma, thyroid cancer and thyroid tumor; The ENT tumor is at least one of oral cancer, tongue cancer, laryngeal cancer, middle ear cancer, gum cancer and orbital tumor; and / or, during the application, the composition is administered by at least one of tumor administration, intravenous administration and intraperitoneal administration; And / or, during application, a single administration dose of the composition is biR OX40 5.75~23 μg / mouse, CpG 25~100 μg / mouse.